Eli Lilly lifts 2026 guidance on robust Q2, pipeline momentum and manufacturing expansion
Aug 5, 2026, 6:47 AM EDT3 sourcesAI-analyzed
Why it may matterVerify against the original reporting
The beat-and-raise earnings narrative, combined with expanding Mounjaro/Zepbound franchises and multiple regulatory milestones, typically prompts short-term upside. However, elevated IPR&D charges temper GAAP earnings, so the upside may be moderated by profit-quality concerns and optics around acquisitions. Historically, Lilly has shown stock moves on strong guidance and pipeline news, supporting a near-term rally.
AI summary
What happened, with direct paths to the underlying reporting
Eli Lilly delivered a strong Q2 2026, with revenue of $23.0B (+48% YoY) driven by Mounjaro and Zepbound, and both GAAP and non-GAAP EPS beating prior guidance. The company raised 2026 revenue guidance to $85–$87B and non-GAAP EPS to $35.50–$36.50, partially offset by $3.03B in acquired IPR&D charges. Regulatory and pipeline progress, plus aggressive manufacturing expansion, position Lilly for continued growth into 2027.
Q2 2026 revenue $23.0B, up 48% YoY, led by Mounjaro/Zepbound.
2026 revenue guidance raised to $85–$87B; non-GAAP EPS $35.50–$36.50.
Regulatory progress: CHMP recommends Jaypirca; FDA approves EBGLYSS (lebrikizumab) for AD.
Mounjaro $9.9B globally; Zepbound US $4.9B; Indiana capex $4.5B expansion.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
A new study suggests staying on low starter doses of GLP-1 obesity therapies yields weight loss with notably less nausea than higher doses. This could influence prescribing patter…
Eli Lilly and Merida Biosciences announced a definitive agreement for Lilly to acquire Merida for up to $2.875 billion in cash, with closing expected in Q4 2026. MER511 data in Ph…
Eli Lilly’s Mounjaro received FDA approval to lower major cardiovascular events in adults with type 2 diabetes at high risk. The SURPASS-CVOT trial, the largest head-to-head cardi…
The FDA cleared Roche and Eli Lilly's blood test to identify signs of Alzheimer's in adults aged 55 and older with cognitive decline. The milestone could accelerate commercializat…
